Ziyaad Waja to Tuberculosis
This is a "connection" page, showing publications Ziyaad Waja has written about Tuberculosis.
Connection Strength
0,929
-
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes. Emerg Infect Dis. 2025 Mar; 31(3):467-476.
Score: 0,162
-
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials. Am J Respir Crit Care Med. 2023 05 15; 207(10):1376-1382.
Score: 0,143
-
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589.
Score: 0,141
-
Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response. Front Cell Infect Microbiol. 2022; 12:1064148.
Score: 0,140
-
Supplementation of sputum cultures with culture filtrate to detect tuberculosis in a cross-sectional study of HIV-infected individuals. Tuberculosis (Edinb). 2021 07; 129:102103.
Score: 0,125
-
Subclinical tuberculosis and adverse infant outcomes in pregnant women with HIV. Int J Tuberc Lung Dis. 2020 07 01; 24(7):681-685.
Score: 0,117
-
Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa: The Tshepiso Study. Clin Infect Dis. 2018 03 05; 66(6):921-929.
Score: 0,100